[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"telitacicept\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:telitacicept":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,60,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630695","efficacy-and-safety-of-telitacicept-combined-with-baricitinib-for-refractory-rheumatoid-arthritis-100630695",false,"NCT07491016","Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis","A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)","Inclusion Criteria:\n\n* 1\\. Age 18-85 years\n* 2\\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria\n* 3\\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological\u002Ftargeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients\n* 4\\. Voluntarily provided written informed consent\n\nExclusion Criteria:\n\n* 1\\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)\n* 2\\. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)\n* 3\\. History of allergy\u002Fhypersensitivity to the study medications (Telitacicept or Tofacitinib)\n* 4\\. Active tuberculosis or active infectious diseases requiring systemic treatment\n* 5\\. Pregnancy, lactation, or refusal to use contraception during the study\n* 6\\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due\n* to:Non-adherence or Severe adverse reactions\n* 7\\. Other conditions contraindicating participation per investigator judgment","ALL","18 Years","85 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients",[25,26,27],"Telitacicept","Treatment Compliance","Rheumatoid Arthritis","RECRUITING","2026-03-24",{"date":31,"type":32},"2026-03-30","ACTUAL",{"date":34,"type":21},"2026-03-01",{"date":36,"type":21},"2028-03-30",{"name":38,"class":39},"Zhejiang Provincial People's Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":40},"100591349","efficacy-and-safety-of-telitacicept-combined-with-tofacitinib-for-refractory-rheumatoid-arthritis-100591349","NCT06979271","Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis","Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Telitacicept in Combination With Tofacitinib","Inclusion Criteria:\n\n1. Age 18-85 years\n2. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria\n3. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological\u002Ftargeted disease-improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients\n4. Voluntarily provided written informed consent -\n\nExclusion Criteria:\n\n1. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)\n2. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)\n3. History of allergy\u002Fhypersensitivity to the study medications (Telitacicept or Tofacitinib)\n4. Active tuberculosis or active infectious diseases requiring systemic treatment\n5. Pregnancy, lactation, or refusal to use contraception during the study\n6. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due to: Non-adherence or Severe adverse reactions\n7. Other conditions contraindicating participation per investigator judgment -",{"count":49,"type":21},20,"The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients",[25,26,27],"2025-05-15",{"date":54,"type":32},"2025-05-18",{"date":56,"type":21},"2025-06-01",{"date":58,"type":21},"2027-04-30",{"name":38,"class":39},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":40},"100566393","efficacy-and-safety-of-telitacicept-in-igan-100566393","NCT06654596","Efficacy and Safety of Telitacicept in IgAN","A Multicenter, Randomized, Controlled Clinical Study on the Efficacy and Safety of Telitacicept in Patients with IgA Nephropathy","Inclusion Criteria:\n\n1. 18-70 years old, male or female\n2. Primary IgA nephropathy confirmed by renal biopsy.\n3. Urine protein ≥ 0.75g\u002F24h or 24-hour urine protein creatinine ratio (PCR) ≥ 0.6 g\u002Fg.\n4. eGFR ≥ 25 ml\u002Fmin\u002F1.73 m2 calculated using the CKD-EPI formula.\n5. Received treatment with ACEI\u002FARB for 12 weeks before randomization, and the drug dose (within the maximum tolerated range) was stable within 4 weeks before randomization.\n6. Use of SGLT2, MRA, hydroxychloroquine, and etc. remained unchanged.\n7. Voluntarily participated in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with abnormal laboratory indicators (see study protocol for details).\n2. Secondary IgA nephropathy such as Henoch-Schonlein purpura, SLE, cirrhosis, etc.\n3. Use of systemic glucocorticoids\u002Fimmunosuppressants within 3 months (such as cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, tripterygium wilfordii, etc.).\n4. Use of biological agents within 6 months (rituximab, etc.).\n5. Active infection, such as active tuberculosis, active hepatitis, hepatitis C, herpes zoster, HIV, etc. According to the results of the five hepatitis B test: patients with positive HBsAg should be excluded; patients with negative HBsAg but positive HBcAb, regardless of whether HBsAb is positive or negative, need to test HBV-DNA to determine their situation: if HBV-DNA is positive, the patient needs to be excluded; if HBV-DNA is negative, the patient can participate in the trial.\n6. COVID-19 infection within 2 weeks before randomization.\n7. Live vaccine within 4 weeks before randomization.\n8. History of malignant tumor within five years.\n9. Uncontrolled hypertension (systolic blood pressure\\>140mmHg or diastolic blood pressure\\>90mmHg).\n10. Poorly controlled diabetes (glycosylated hemoglobin\\>8%).\n11. Pregnant women and breastfeeding women.\n12. Participating in other clinical trials at the same time.\n13. Surgery, chemotherapy, radiotherapy and other treatments are planned during the study.\n14. Other reasons judged by researchers as unsuitable for inclusion in the study.","70 Years",{"count":69,"type":21},118,"INTERVENTIONAL",[72],"NA","A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.",[75,76,25,77],"IgA Nephropathy (IgAN)","Kidney Diseases","Glucocorticoid","2024-12-30",{"date":80,"type":32},"2025-01-01",{"date":82,"type":32},"2024-12-06",{"date":84,"type":21},"2026-12",{"name":86,"class":39},"Ruijin Hospital",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":94,"maxAge":17,"enrollmentInfo":95,"targetDuration":4,"studyType":70,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":40},"100525720","phase-3-study-of-the-telitacicept-in-pediatric-patients-with-frequently-relapsing-or-steroid-dependent-nephrotic-syndrome-100525720","NCT06125405","Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome","STERN","Inclusion Criteria:\n\n* Sensitive but frequent relapses or steroids dependence nephrotic syndrome\n* Age: 2 to 18 years old\n* Normal renal function: estimated glomerular filtration rate ≥90ml\u002F min\u002F1.73m2\n* Morning urine protein \\\u003C1+ or urine protein-creatinine ratio \\\u003C0.2g\u002Fg (\\\u003C20 mg\u002F mmol) for 3 consecutive days and above when in enroll\n* No rituximab was used within 6 months, no tacrolimus, mycophenolate mofetil, cyclosporine A, or cyclophosphamide was used within 3 months, no ACTH was used within 3 months prior to the enrollment\n\nExclusion Criteria:\n\n* Family history of nephrotic syndrome, chronic glomerulonephritis or uremia\n* Leukopenia (White Blood Cells ≤ 3.0 \\* 10\\^9 \u002F L)\n* Moderate to severe anemia (hemoglobin \\\u003C9.0 g\u002FdL)\n* Thrombocytopenia (platelet count \\\u003C100\\*10\\^12\u002FL)\n* Positive Hepatitis B virus serological indicators (Hepatitis B surface antigen or \u002F and Hepatitis B virus e antigen or \u002F and Hepatitis B core antibody), Hepatitis C virus-positive or patients with abnormal liver function (2 or more times of alamine aminotransferase or total bilirubin was exceeded the normal value, and continued to rise for 2 weeks)\n* There are chronic active infections such as Epstein-Barrvirus, cytomegalovirus or Mycobacterium tuberculosis, and the usage of steroids and immunosuppressive agents may aggravate the state of an illness\n* Secondary nephrotic syndrome (such as purpuric nephritis, lupus nephritis, etc.)\n* Those who with hematological or endocrine system diseases as well as serious organs illness such as heart, liver or kidney\n* Those who with other autoimmune diseases or primary immunodeficiencies or tumors\n* Those who have participated in other clinical trials within three months prior to the enrollment\n* Those who was not suitable for participating this study judged by investigator","2 Years",{"count":49,"type":21},[97],"PHASE3","The main objective is to evaluate the effectiveness of telitacicept in pediatric patients with frequently relapsing or steroid dependent nephrotic syndrome within the 52-week follow-up.",[100,25],"Nephrotic Syndrome in Children",[25,102,103],"Frequently Relapsing Nephrotic Syndrome","Steroid Dependent Nephrotic Syndrome","2024-08-20",{"date":106,"type":32},"2024-08-21",{"date":108,"type":32},"2023-11-28",{"date":110,"type":21},"2027-10-24",{"name":112,"class":39},"The Children's Hospital of Zhejiang University School of Medicine"]